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Abstract
Background: There is increasing evidence that chronic inflammation is an
important determinant in insulin resistance and in the pathogenesis of type 2
diabetes (T2D). MicroRNAs constitute a newly discovered system of cell regulation
and in particular two microRNAs (miR-146a and miR-155) have been described as
regulators and biomarkers of inflammation.
Aim: To determine a putative association between the levels of miR-146a and miR-
155 in serum of T2D patients, clinical parameters and serological indicators of
inflammation.
Methods: We performed quantitative Real Time PCR (qPCR) of microRNAs from
serum (56 Ecuadorian T2D ambulatory patients and 40 non-diabetic controls). In
addition, we evaluated T2D-related serum cytokines.chemokines and growth
factors using a commercially available multi-analyte cytometric bead array system.
We correlated outcomes to clinical parameters, including BMI, HbA1c and lipid
state.
Results: The Ecuadorian non-diabetic controls appeared as overweight (BMI.25:
patients 85%, controls 82.5%) and as dyslipidemic (hypercholesterolemia: patients
60.7%, controls 67.5%) as the patients.
- The serum levels of miR-146a were significantly reduced in T2D patients as
compared to these non-diabetic, but obese/dyslipidemic control group (mean
patients 0.61, mean controls set at 1; p50.042), those of miR-155 were normal.
- The serum levels of both microRNAs correlated to each other (r50.478; p,0.001)
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and to leptin levels. The microRNAs did not correlate to BMI, glycemia and
dyslipidemia.
- From the tested cytokines, chemokines and growth factors, we found IL-8 and
HGF significantly raised in T2D patients versus non-diabetic controls (p50.011 and
0.023 respectively).
Conclusions: This study shows decreased serum anti-inflammatory miR-146a,
increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair
factor) as discriminating markers of failure of glucose control occurring on the
background of obesity and dyslipidemia.
Introduction
It is well accepted that obesity and type 2 diabetes can be viewed as inflammatory
disorders. Early, in the 1990s Hotamisligi et al. showed that TNF-a was present in
obese individuals and animals in proportional levels to insulin resistance and they
proposed a pathogenic role of inflammatory molecules, such as TNF-a, in the
development of insulin resistance and diabetes [1]. To support this idea it was
later shown that TNF-a was indeed capable to induce insulin resistance in lean
animals [1–3] and that various pro-inflammatory cytokines trigger intracellular
pathways such as Nuclear Factor for Kappa light chain in B-cells (NF- kB), IkB
kinase-b (IKKb) and Jun kinase (JNK) which are capable to inhibit the insulin
signaling pathway [4–8].
Macrophages in adipose tissue as well as the adipocytes themselves are the
prime source of the raised pro-inflammatory cytokines and adipokines, leading to
a chronic pro-inflammatory state in obese subjects. In conjunction with these
cellular responses in so-called ‘‘chronically inflamed’’ adipose tissue, a disturbed
lipid metabolism is capable of inducing such a chronic pro-inflammatory state.
High levels of Ox-LDL and low levels of HDL correlate to inflammatory activation
and insulin resistance through a mechanism called lipotoxicity [4, 9–11].
Moreover, free fatty acids enhance the secretion of TNF-a, IL-6 and PAI-1, which
stimulate macrophages to secrete more inflammatory cytokines and chemokines
aggravating the feed-forward loop of inflammation [2, 11, 12]. All in all, there is a
vast literature on increased levels of pro-inflammatory cytokines in the metabolic
syndrome (MetS) and type 2 diabetes (T2D), and excellent reviews exist on this
topic [13–17].
MicroRNAs represent a newly discovered level of cell regulation, functioning by
inhibiting protein translation, and microRNAs have been suggested to be useful
biomarkers in various pathological conditions, including diabetes [18, 19]. A
substantial literature indicates that two microRNAs, i.e. miR-146a and miR-155,
are key regulators of (auto)-inflammatory processes [20–31]. Dysregulation of
these microRNAs in peripheral blood mononuclear cells (PBMC) has been
implicated in diabetes [20, 32]. MiR-146a and miR-155 expression levels have
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been found to be significantly decreased in the PBMCs of patients with T2D as
compared to control subjects and expression values correlated negatively to
parameters of metabolic control (Hb1Ac, glucose) and signs of inflammation
(NFkB mRNA levels in PBMC, circulatory levels of pro-inflammatory cytokines).
MicroRNAs are, however, also detectable in serum and there are indications that
microRNAs are very stable in this milieu [33–36], although they might be less
stable in other milieus, such as the brain [37]. Measured in serum, they can serve
as biomarkers and there is a study that has determined the level of miR-146a in
the serum of T2D patients as one of the microRNAs of a set of 7 microRNAs
considered to act as key regulators of the expression, production, secretion or
effectiveness of insulin [38]. This study found raised levels of these 7 microRNAs
when evaluated in relatively small groups (n519 each) of newly diagnosed T2D
patients as compared to pre-diabetic individuals and T2D-susceptible individuals
[38].
In the current study we determined the levels of miR-146a and miR-155a in the
serum of 56 Ecuadorian T2D patients and of 40 non-diabetic controls and
associated the levels of these microRNAs to parameters of glucose control,
dyslipidemia, obesity and the serum level of 12 T2D-related inflammatory
mediators (TNFa, IL-1b, IL-6, NFG, HGF, PAI, Resistin, CCL2, Adiponectin,
Leptin, IL-8, and CCL4) using a commercially available multi-analyte cytometric
bead array system, especially developed for type 2 diabetes (Milliplex Map,
U.S.A.).
Patients and Methods
Patients
A total of 56 patients positively diagnosed with type 2 diabetes, according to the
criteria of The Expert Committee on the diagnosis and clasification of Diabetes
Mellitus [39], were recruited in 4 medical centers of Quito-Ecuador (Eugenio
Espejo Hospital, Club de Leones Sur, Fundacio´n Oftalmolo´gica del Valle and
Fundacio´n de la Psoriasis) from 2009 til 2012. Patients with immune disorders,
serious medical illness, recent infections (last 2 weeks), obvious vascular
complications, fever, pregnancy/postpartum, use of statins and LADA patients
(positive GAD-65 Abs) were excluded. Forty non-diabetic controls taken from the
same ethnic and societal background, not suffering from important medical
disorders (including acute infection) served as controls. They were included at the
same time as the patients and had to be over 30 years of age and preferably of the
same gender as the patients. The Medical Ethical Review Committee of the
Ecuadorian Corporation of Biotechnology Quito, Ecuador approved the study.
Written informed consent was obtained from the patients and controls in the
study. The Ethic Committee of the Central University also validated the ethical
approval of the study. The Ecuadorian Ministry of Health (MSP) gave the
respective permit to export and process the samples in Erasmus MC, Rotterdam,
The Netherlands.
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Serum cytokines and lipid profile
In the morning fasting venous peripheral blood (10 mL) was collected in a
clotting tube and processed within 4 hours. Serum was frozen and stored at minus
80 C˚ for approximately 24 months before testing. The levels of TNFa, IL-1b, IL-6,
NGF, HGF, PAI, Resistin, CCL2 (MCP-1), Adiponectin, Leptin, IL-8, and MIP1b
(CCL4) were measured by flow cytometry (BD LSR II Biosciences, California, and
EE.UU.) using a commercially available multi-analyte cytometric bead array
system (Milliplex Map, U.S.A.). The data were analyzed using a 5-parameter
logistic method for calculating analyte concentrations in samples (MAGPIX with
xPONENT software, Luminex, Austin, USA). Undetectable serum analyte levels
were considered as 0 pg/ml and included in the statistical analysis. The lipid
profile was performed according to standard lab procedures in Quito-Ecuador
(AMCOR laboratory) and assays were validated in Erasmus MC.
MicroRNA quantitative real-time PCR (qPCR)
Total RNA was isolated from serum using the Qiagen miRNeasy kit (Qiagen,
Hilden, Germany). In order to correct for variations in RNA isolation derived, we
spiked-in a non-human (C. elegans) synthetic miRNA cel-miR-39 miRNA Mimic
(MSY000010) into the sample before nucleic acid isolation. Subsequently, specific
stem-looped reverse transcription primers were used to obtain cDNA for mature
microRNAs. The RNA was reverse transcribed using the TaqMan MicroRNA
Reverse Transcription Kit from Applied Biosystems, The Netherlands (ABI). PCR
was performed using pre-designed TaqMan microRNA assays and TaqMan
Universal Master Mix, NoAmpEraseUNG, with an ABI 7900 HT real-time PCR
machine. The PCR conditions were 2 min at 50 C˚, 10 min at 95 C˚, followed by 40
cycles of 15 s at 95 C˚, and finally 1 min at 60 C˚. The spiked-in syn-cel-miR-39
goes through the entire RNA isolation process and serves as endogenous control
for data normalization.
TaqMan assay data processing
SDS software (ABI) was used to collect the data and the RQ Manager Program
(ABI) was used to assign, check and standardize CT values. Data Assist software
was used to normalize the data to the syn-cel-miR-39. For threshold cycles below
40, the corresponding microRNA was considered detected, higher cycle numbers
were not included in the calculations. The results were represented using the
ddCT method (2 –ddCT, User Bulletin, ABI).
Data analysis
Statistical analysis was performed using SPSS 20 (IBM, Inc.) package for
Windows. Data were tested for normal distribution using the Kolmogorov-
Smirnov test. The Grubbs’ test for outlier detection was applied (http://graphpad.
com/support/faqid/1598/). Depending on the distribution pattern and the total
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number of subjects, parametric (normal distribution, independent t test) or
nonparametric group comparison (Mann-Whitney U test) were applied.
Correlations were determined by Spearman correlation. Level of significance were
set at p50.05 (two tailed). A dendrogram visualizing associations was constructed
in SPSS using hierarchical cluster analysis of the serum cytokines using the
between-groups linkage method. Hierarchical regression analysis was used to test
if means of miR-146a, IL-8 and HGF were significantly different between Non
diabetic controls and T2D patients, when controlling for BMI and lipids. Graphs
were designed with GraphPad Prism 5.04 (GraphPad Software, Inc.) for
Windows.
Results
Patient and control characteristics
Table 1 shows the number of patients and non-diabetic controls used for this
study and their ages, gender, HbA1c/hyperglycemia, BMI, lipid profile and
medication. As expected, the T2D patients had a significantly higher fasting
glucose and HbA1c level as the non-diabetic controls. 70% of the patients used
oral anti-diabetic treatment and 30% used insulin. Of the patients 61% had a
history of cardiovascular disease, while 48% had a family history (1st, 2nd degree)
of diabetes (values were 29% and 29% respectively for the non-diabetic control
group).
With regard to the non-diabetic control group, we selected the controls by
asking hospital staff (60%) and accompanying care takers (40%) to volunteer to
donate blood at the same time as the patients were investigated. Controls needed
to be over 30 years of age, while we tried to match as much as possible for gender.
Table 1 show that we did not completely succeed in matching for age, since our
controls were on average 8 years younger than the T2D patients. Gender
distribution was not significantly different with a slight over representation of
women in the control group.
We found the collected non-diabetic controls to be as overweight as the patients
with a normal BMI in only 17.5% of the 40 non-diabetic controls as compared to
14.8% of the 56 T2D patients. There were no differences in BMI between non-
diabetic hospital staff and non-diabetic care-takers. The T2D patients and non-
diabetic controls also appeared to have the same disturbed lipid profile; the non-
diabetic controls had hypercholesterolemia in 67.5% of individuals, the T2D
patients had a hypercholesterolemia in 60.7% of cases (for further details see
Table 1). There were again no differences between non-diabetic hospital staff and
non-diabetic care-takers with regard to dislipidemia.
MicroRNA’s, cytokines, chemokines and growth factors in serum
Table 2 gives the mean and standard error of the mean (SEM) of the fold change
values of the two tested microRNAs (146a and 155 versus the reference
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Table 1. Patients and Non-diabetic controls characteristics.
Controls T2D Controls
Vs.
T2D
p- Value
Group size n 40 56
Age mean (range) 54 (32–87) 62 (38–85) 0.002
Gender
Female n (%) 28 (70%) 34 (61%) NA
Male n (%) 12 (30%) 22 (39%) NA
Comorbidities
Cardiovascular diseases n (%) 29% 61% NA
Familiar antecedents of diabetes n (%) 29% 48% NA
BMI mean (range) % 29.3 (23–42) Normal 17,5% 29.2 (22–39) Normal 14,8% 0,86
Overweight 47,5% Overweight 46,4%
Obese 35% Obese 38,8%
Glucose state
Fasting Glucose mg/dL 86 (60.9–180.5) Normal 95% 144 (69–397) Normal 51.8% 0.00**
mean (range) %
High 5% High 48.2%
HbA1C 5.7 (3.9–6.7) Normal 95% 7.1 (4.8–12.5) Normal 35.7% 0.00**
mean (range) %
High 5% High 64.3%
Lipid Profile
Cholesterol mg/dL 235 (131–328) Normal 32.5% 233 (143–436) Normal 39.3% 0,92
mean (range) %
High 67.5% High 60.7%
TG mean mg/dL 200 (92–547) Normal 62.5% 197 (76–411) Normal 66.1% 0,88
mean (range) %
High 37.5% High 33.9%
HDL mean mg/dL 41.5 (25–65) Normal 45% 43 (18–70) Normal 58.9% 0,71
mean (range) % Low 55% Low 41.1%
LDL mg/dL 155 (78–266) Normal 57.5% 153 (77–361) Normal 62.5% 0,92
mean (range) %
High 42.5% High 37.5%
Medication
Oral Anti-diabetic treatment 0% 70%
Insulin treatment 0% 30%
Aspirin 21% 30%
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syn-cel-miR-39) in the serum of the T2D patients as compared to the non-
diabetic controls. The serum levels of miR-146a were significantly reduced in T2D
patients as compared to the non-diabetic controls (Fig. 1), those of miR-155 were
not. Nevertheless there existed a good correlation between the serum levels of
both microRNAs (r50.478; p,0.001).
Fig. 2 shows the unsupervised cluster analysis of the levels of the microRNAs
and the tested T2D-related cytokines, chemokines and growth factors in the
serum of patients and non-diabetic controls. As can be seen from the diagram
Table 1. Cont.
Controls T2D Controls
Vs.
T2D
p- Value
Statins (%) 0% 0%
Values in bold denote a significant difference between two groups.
Table 1 shows the number of patients and controls used in this study and their ages, gender, comorbidities, HbA1c/hyperglycemia, BMI, lipid profile and
medication use.
doi:10.1371/journal.pone.0115209.t001
Table 2. Cytokines, chemokines and growth factors in Non-diabetic controls and T2D patients.
Controls vs. T2D
T2D T test
N Mean (SEM) p-Value
NGF 56 1,24 0,36 0,707
IL1beta 56 0,79 0,18 0,686
IL6 56 1,38 0,21 0,131
CCL4 56 0,92 0,1 0,775
HGF 56 1,34 0,09 0.023*
TNFalpha 56 1,11 0,07 0,22
Resistin 56 1,19 0,08 0,097
IL8 56 2,19 0,36 0.011*
Adiponectin 56 1,25 0,14 0,222
CCL2 56 1,00 0,07 0,883
miR146a 56 0,61 0,05 0.042*
miR155 56 0,93 0,07 0,844
Leptin 56 0,86 0,11 0,338
PAI1 56 1,17 0,23 0,565
Values in bold denote a significant difference between two groups
Group size, mean and SEM in the order of the cluster analysis. To avoid inter-assay variation, serum levels (pg/ml) were expressed in fold change compared
to non-diabetic controls, the average of the Controls in each assay was set to one. Differences between groups were tested using independent T test. Levels
of significance were set at p50.05 (two-tailed).
doi:10.1371/journal.pone.0115209.t002
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there was the expected strong clustering of both microRNAs, which also clustered
to some extent with leptin. With regard to the other cytokines and chemokines,
there existed a clustering of the pro-inflammatory mediators CCL4, IL-6, IL-1b
and NGF, and between TNF-a, IL-8, HGF and resistin. To avoid inter-assay
variation, serum levels were expressed in fold changes compared to controls for
each mediator.
Table 2 gives the relative levels of the tested cytokines, chemokines and other
mediators in the serum of the T2D patients and non-diabetic controls in the order
of the cluster analysis. From the factors determined, only the levels of IL-8 and
Fig. 1. Expression level of serum miR-146a in Ecuadorian Non-diabetic controls and T2D patients.
Fig. 1 shows mean and standard deviation of the fold change values of miR-146a (reference microRNA sync-
cel-mir-39) in the serum of the T2D patients as compared to Non-diabetic controls. Differences between
groups were tested using independent T test. Levels of significance were set at p50.05 (two-tailed).
doi:10.1371/journal.pone.0115209.g001
Fig. 2. Dendrogram of unsupervised hierarchical cluster analysis of the tested serum levels of
microRNAs, cytokines, chemokines and growth factors in T2D patients and Non-diabetic controls. The
dendrogram shows the clustering of miR-146a and miR-155, and of the pro-inflammatory cytokines CCL4, IL-
6, IL-1b and NGF and of TNF-a, IL-8, HGF and resistin.
doi:10.1371/journal.pone.0115209.g002
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HGF appeared to be significantly different between T2D patients and the non-
diabetic controls. Both IL-8 and HGF levels were higher in the serum of the T2D
patients as compared to the non-diabetic controls. Resistin was also higher in the
serum of the patients, but only approached the level of significance (p50.09). All
in all, the picture emerges of particularly the cluster of HGF, TNF-a, Resistin and
IL-8 to be raised in the serum of the diabetic patients versus the non-diabetic
controls.
The correlations of the level of the microRNAs with the cytokines/
chemokines/growth factors and clinical variables
We performed correlation analyses between the different parameters measured
and only took correlations with a level of p,0.01 into consideration.
Since our patients and non-diabetic controls differed 8 years in age we took
special notice of correlations with age. The microRNAs did not correlate with age.
Of the cytokines HGF, resistin and adiponectin correlated positively to age. It is
important to note that correction for age did not change the association of HGF
with disease (r50.258, p50.008). Of the clinical variables HbA1c levels correlated
to age.
It is also of note that the levels of miR-146a and miR-155 correlated to each
other, corroborating our findings in the cluster diagram. With regard to
correlations of microRNAs with cytokines we found miR-146a to correlate
significantly and positively to the serum PAI level (r50.259; p50.01). There were
no correlations of miR-146a and clinical variables. The serum miR-155 level
correlated significant to the serum leptin level (r50.326, p50.001) and IL-8
(r50.268, p50.008).
Serum IL-8 levels correlated to HbA1c levels (r50.301; p50.003) and also
positively to TNFa levels (r50.288, p50.004), which in turn correlated to HGF
levels (r50.367; p50.000), corroborating our findings in the cluster diagram
(Fig. 2). Positive correlations were also found between HGF and resistin levels and
resistin and IL-6 levels, again corroborating the findings in the cluster diagram
(Fig. 2).
Expected significant correlations were between leptin and BMI and leptin and
leptin and gender.
Discussion
In this study we determined two inflammation-related microRNAs in the serum
of Ecuadorian T2D patients. We observed a significantly reduced level of one of
these microRNAs, i.e. of miR-146a, in the serum of T2D patients as compared to a
non-diabetic control group. Reduced expression of miR-146a is classically
considered a sign of a pro-inflammatory state. Boldin et al. described that miR-
146a-null mice systematically overproduce pro-inflammatory cytokines (such as
TNF-a, IL-6 and IL-1b) in response to injection with a sub-lethal LPS dose. Tissue
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macrophages were the primary source of this enhanced pro-inflammatory
cytokine production. This implicates miR-146a in attenuating macrophage
inflammatory responses [40]. In agreement with these results, in vitro studies
show that induction of miR-146a expression in monocyte/macrophage cell lines
negatively regulates the inflammatory response [23, 41], while transfection with
miR-146a inhibitors in both resting and LPS-stimulated macrophage-like cell lines
had an opposite effect and resulted in an up-regulation of these inflammation-
related genes. Collectively these data show that miR-146a is a strong down
regulator of the production of classical inflammatory compounds in macro-
phages.
We also found the level of serum IL-8 significantly up regulated in the T2D
patients as compared to the non-diabetic controls in agreement with previous
findings of Herder et al [42]. IL-8 is considered a primary cytokine for M1
inflammatory macrophages. On the basis of these significant alterations in miR-
146a and IL-8 levels we like to conclude that our study supports the concept of an
activation of the inflammatory response system in T2D patients. The correlation
of the IL-8 level with Hb1Ac supports the idea that chronic hyperglycemia plays at
least a partial role in this activation.
A limitation of our study is that our non-diabetic control group was not
matched for age to our diabetic patient group, and non-diabetic controls were on
average 8 years younger than our patients; patients and non-diabetic controls did
have similar readings for lipid profiles and BMI. In correlation analysis miR-146a
levels and IL-8 levels appeared not to be dependent of age. When we performed
hierarchical regression analysis for BMI and lipid profiles, it appeared that the
disease state always was the determinant for abnormal miR-146a and IL-8 levels
and that BMI and lipid profiles did virtually not determine these levels, except for
IL-8 which was also determined by the cholesterol levels (see S1 and S2 Table).
We are thus confident that indeed abnormal levels of miR-146a and IL-8 are
determined by the T2D state in this study.
A reduced level of miR-155 has been described in the circulating leukocytes of
T2D patients [32]. However we were not able to find a significant change of miR-
155 in the serum of T2D patients as compared to our non-diabetic control group.
We however did find a significant positive correlation between the serum levels of
miR-155 and miR-146a and we found a clustered expression of both miR-146a
and miR-155 with leptin in cluster analysis. Since leptin is primarily derived from
adipose tissue, this might suggest that a significant proportion of the circulating
microRNAs miR-146a and miR-155 is produced by activated macrophages and
adipocytes in adipose tissue.
Our T2D cases lacked a significant over-expression of several classical pro-
inflammatory compounds in serum: similar levels of TNF-a, IL-1b and IL-6 were
found in the serum of patients and non-diabetic controls. This contrasts to
previous findings by others, such as Costantini et al., who observed increased
levels of IL-1a, leptin, resistin and PAI-1 in T2D patients [43]. Our negative
findings might be due to the fact that our non-diabetic controls appeared to have
many signs of the metabolic syndrome: BMI values were over 25 in 82.5%
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(average BMI 29.3), while hypercholesterolemia was present in 67.5% with raised
LDL in 42.5% of non-diabetic controls. These values were similar to the ones
found in the T2D cases. The Ecuadorian non-diabetic control group was
composed of care-takers (40%, friends and family), and hospital staff (60%) from
the Quito area. Considering this excessively high prevalence of obesity and
dyslipidemia in the Quito non-diabetic control group, it is important to note that
a recent healthcare report of the Ecuadorian government corroborates this high
prevalence of obesity and dyslipidemia in urban Ecuadorian populations [44].
In a parallel study we have collected Dutch T2D patients and Dutch non-
diabetic controls that were tested at the same time with the same multi-analyte
system for cytokines and growth factors. The Dutch healthy controls had on
average a BMI of 23.8 and had normal lipid values (hypercholesterolemia none,
raised LDL 14%). Interestingly our Ecuadorian ‘‘healthy’’ control group indeed
had higher levels of CCL4 and IL-6 (see S4 Table), suggesting that in particular
obesity and dyslipidemia determine a higher level of these classical pro-
inflammatory cytokines in serum, and not (only) the diabetes state and/or
pathology per se.
Reduced levels of miR-146a have previously been found in T2D patients, be it
in circulating leukocytes [20]. However, our report contrasts with another report
that showed elevated levels of miR-146a in the serum of newly diagnosed T2D
patients [38]. These elevated levels were found in comparison to the serum levels
of pre-diabetic individuals with a disturbed OGT and T2D-susceptible individuals
(family), who only had a moderate overweight (average BMI of 26) and moderate
hypercholesterolemia (average 5.6 mmol/l), as had the newly T2D cases in that
study. We therefore assume that the distinct status of the control population with
regard to obesity and/or severe dyslipidemia might have played a role in the
differences. In addition, our T2D patients had longstanding diabetes, and the
stage of disease may have played a role as well.
Apart from the involvement of inflammatory miR-146a and IL-8, our study
suggests an involvement of other molecular systems associated with the failure to
control glucose homeostasis on the background of an already existing obesity and
dyslipidemia.
First, significantly higher serum levels of HGF were found in the T2D patients
as compared to the non-diabetic controls. HGF levels correlated to age, but
correction for age left the association with T2D intact (similar results were
obtained with corrections for BMI and dyslipidemia, see S3 Table). HGF was first
described as a hepatocyte factor involved in liver regeneration after partial
hepatectomy [45]. Recent evidence shows that the factor is also produced by
monocytes and macrophages and that it is involved in various regeneration
processes, including vascular repair and b cell growth [46–48]. HGF can thus be
viewed as a key factor in insulin resistance-associated compensatory mechanisms
at the level of the pancreatic islet by stimulating its regeneration and at the level of
the vasculature by stimulating repair of hyperglycemia-damaged vessels by
inducing proliferation of endothelial cells. In marked contrast, however, HGF has
also been implicated with a pathogenic role in macrovascular disease as HGF
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levels in type 2 diabetes patients correlated positively with carotid intimal-media
thickness and plaque score [49].
In addition to a higher level of HGF there was also an over-expression (non-
significant, p50.09) of resistin in the serum of the Ecuadorian T2D cases as
compared to the non-diabetic controls. Resistin was initially identified in
adipocytes, but significant levels of resistin expression in humans are mainly
found in immune cells, particularly monocytes [50, 51]. Resistin was first
described as a factor contributing to the development of insulin resistance and
diabetes in humans, but debate is still ongoing regarding its role in obesity, insulin
sensitivity and the development of T2D. In addition also evidence for a
pathogenic role of resistin in atherogenic vascular diseases is growing [52, 53].
In conclusion this study shows signs of chronic inflammation (decreased serum
anti-inflammatory miR-146a/increased IL-8) and signs of islet and vascular repair
(increased HGF) in patients with a failure to control glucose homeostasis when
compared to non-diabetic controls with a similar prevalence of obesity and
dyslipidemia. Our study also suggests that miR-146a can be considered as a serum
biomarker of the inflammatory process linked to the failure of glucose control of
the T2D state against a background of obesity and dyslipidemia.
Supporting Information
S1 Table. Hierarchical Regression Model of miRNA-146a. Hierarchical
regression analysis for BMI and lipid profiles shows that the disease state was the
determinant for abnormal miR-146a.
doi:10.1371/journal.pone.0115209.s001 (DOCX)
S2 Table. Hierarchical Regression Model of IL-8. Hierarchical regression analysis
for BMI and lipid profiles shows that the disease state and cholesterol levels were
the determinant for abnormal IL-8.
doi:10.1371/journal.pone.0115209.s002 (DOCX)
S3 Table. Hierarchical Regression Model of HGF. Hierarchical regression
analysis for BMI and lipid profiles shows that the disease state was the
determinant for abnormal HGF.
doi:10.1371/journal.pone.0115209.s003 (DOCX)
S4 Table. Cytokines and chemokines mediators of Ecuadorian Non-diabetic
controls and Dutch healthy controls. Group size, median, inter-quartile range
(IQR) and p-values obtained by Mann—Whitney U-test is represented. Serum
levels (pg/ml) are shown in the order of the cluster analysis. In a parallel study we
have collected Dutch healthy controls that were tested at the same time with the
same multi-analyte system for cytokines and growth factors. Ecuadorian non-
diabetic controls showed higher levels of the classical pro-inflammatory cytokines
(CCL4 and IL-6).
doi:10.1371/journal.pone.0115209.s004 (DOCX)
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S1 Data. Raw data points of the tested serum levels of microRNAs, cytokines,
chemokines and growth factors of T2D patients and Non-diabetic controls. The
levels of TNFa, IL-1b, IL-6, NGF, HGF, PAI, Resistin, CCL2 (MCP-1),
Adiponectin, Leptin, IL-8, and MIP1b (CCL4) were measured by flow cytometry
(BD LSR II Biosciences, California, and EE.UU.) using a commercially available
multi-analyte cytometric bead array system (Milliplex Map, U.S.A.). MicroRNA
quantitative real-time PCR (qPCR) was performed using pre-designed TaqMan
microRNA, with an ABI 7900 HT real-time PCR machine. SDS software (ABI)
was used to collect the data.
doi:10.1371/journal.pone.0115209.s005 (ZIP)
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